Compare United States Copper Index Fund (CPER) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Copper Index Fund vs Quest Diagnostics Inc — how do they compare? United States Copper Index Fund trades at $39.93, while Quest Diagnostics Inc trades at $236.29 (market cap $26.24B). The key difference: Quest Diagnostics Inc pays a 1.45% dividend while United States Copper Index Fund pays none. Which is the better fit depends on your goals.
| CPER | DGX | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $40.85 | $238.50 |
52-Week Low | $27.57 | $173.49 |
Market Cap | — | $26.24B |
Enterprise Value | — | $32.00B |
Dividend Yield | — | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPER trades at $40.02, down 0.5% on the day, with a bullish technical signal from moving averages and strong trend strength indicated by ADX. Recent news highlights copper's record highs driven by AI infrastructure demand and supply disruptions, though oscillators are neutral. Financial ratios are unavailable, limiting fundamental assessment.
The outlook is supported by structural copper demand from electrification and AI, but risks include price volatility and substitution threats. Analyst sentiment is positive on copper's long-term prospects, though CPER-specific fundamentals require verification from SEC filings for a complete investment view.
Quest Diagnostics (DGX) trades at $236.04, down 0.61% on the day, as the stock consolidates near recent highs following strong Q2 2026 earnings. The company has delivered three consecutive quarterly earnings beats, with Q2 EPS of $3.12 exceeding expectations by 10.6%. Revenue growth accelerated to 10.2% year-over-year, supported by strong testing demand and strategic partnerships. Technical indicators show a bullish trend with the stock trading near pivot point resistance at $238.
The outlook remains positive with raised 2026 guidance and consistent dividend payments, though valuation multiples appear full at 25.2x P/E. Key risks include margin pressure from lower-margin contracts and rising project costs. Analyst consensus leans bullish with a $249.50 price target representing 5.7% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About United States Copper Index Fund
CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
